Promise in cancer care

LEUKAEMIA patients could benefit from a radical new type of bone marrow transplant which cuts the chance of their blood cancer returning.

The method ensures only “good” immune cells from a donor are used, with any “bad” cells that could attack the patient being eliminated first.

Dutch firm Kiadis Pharma is behind the technique called ATIR, which has shown huge promise in early trials.

Chief executive Arthur Lahr said doctors currently had to use a “barbaric” approach.